Материалы доступны только для специалистов сферы здравоохранения. Авторизуйтесь или зарегистрируйтесь.
Нестероидные противовоспалительные препараты: безопасность с позиции доказательной медицины
Нестероидные противовоспалительные препараты: безопасность с позиции доказательной медицины
Аникин Г.С., Стожкова И.В., Кукес В.Г. Нестероидные противовоспалительные препараты: безопасность с позиции доказательной медицины. Consilium Medicum. 2017; 19 (7.2. Хирургия): 28–32. DOI: 10.26442/2075-1753_19.7.2.28-32
________________________________________________
Материалы доступны только для специалистов сферы здравоохранения. Авторизуйтесь или зарегистрируйтесь.
Аннотация
Назначение нестероидных противовоспалительных препаратов (НПВП) в современной клинической практике – рутинная процедура. Однако зачастую не оцениваются все аспекты безопасности приема НПВП. В статье освещены основные аспекты безопасности приема НПВП, которыми должен руководствоваться врач в своей практике.
Ключевые слова: нестероидные противовоспалительные препараты, обезболивание, профиль безопасности.
Key words: nonsteroidal anti-inflammatory drugs, anesthesia, safety profile.
Ключевые слова: нестероидные противовоспалительные препараты, обезболивание, профиль безопасности.
________________________________________________
Key words: nonsteroidal anti-inflammatory drugs, anesthesia, safety profile.
Полный текст
Список литературы
1. Starling AJ, Hoffman-Snyder C. Risk of development of medication overuse headache with nonsteroidal anti-inflammatory drug therapy for migraine: a critically appraised topic. Neurologist 2011; 17 (5): 297–9.
2. Brune K, Patrignani P. New insights into the use of currently available non-steroidal anti-inflammatory drugs. J Pain Res 2015; 8: 105–18.
3. Smyth EM, Grosser T, Wang M et al. Prostanoids in health and disease. J Lipid Res 2009; 50: S423–8.
4. Grosser T, Fries S, FitzGerald GA. Biological basis for the cardiovascular consequences of COX-2 inhibition: therapeutic challenges and opportunities. J Clin Invest 2006; 116: 4–15.
5. Funk CD, FitzGerald GA. COX-2 inhibitors and cardiovascular risk. J Cardiovasc Pharmacol 2007; 50: 470-9.
6. Schmidt M, Lamberts M, Olsen AM et al. Cardiovascular safety of non-aspirin non-steroidal anti-inflammatory drugs: review and position paper by the working group of cardiovascular pharmacotherapy of the European Society of Cardiology. Eur Heart J 2016; 37: 1015–23.
7. Ye Y, Martinez JD, Perez-Polo RJ et al. The role of eNOS, iNOS, and NFkB in upregulation and activation of cyclooxygenase-2 and infarct size reduction by atorvastatin. Am J Physiol Heart Circ Physiol 2008; 295: 343–51.
8. Liuni A, Luca MC, Gori T, Parker JD. Rosuvastatin prevents conduit artery endothelial dysfunction induced by ischemia and reperfusion by a cyclooxygenase-2-dependent mechanism. J Am Coll Cardiol 2010; 55: 1002–6.
9. Johnson AG, Nguyen TV, Day RO. Do nonsteroidal anti-inflammatory drugs affect blood pressure? A meta-analysis. Ann Intern Med 1994; 121: 289–300.
10. Chan CC, Reid CM, Aw TJ. Do COX-2 inhibitors raise blood pressure more than nonselective NSAIDs and placebo? An updated meta-analysis et al. J Hypertens 2009; 27: 2332–41.
11. Trelle S, Reichenbach S et al. Cardiovascular safety of non-steroidal anti-inflammatory drugs: network meta-analysis. BMJ 2011; 342: с7086.
12. McGettigan P, Henry D. Cardiovascular Risk with Non-Steroidal Anti-Inflammatory Drugs: Systematic Review of Population-Based Controlled Observational Studies. PLoS Med 2011; 8 (9): e1001098.
13. https://www.fda.gov/Drugs/DrugSafety/ucm451800.htm
14. Nagata N, Niikura R et al. Lower GI bleeding risk of nonsteroidal anti-inflammatory drugs and antiplatelet drug use alone and the effect of combined therapy. Gastrointest Endosc 2014, Aug 1.
15. Евсеев М.А. НПВП-индуцированные гастродуоденальные язвы, осложненные кровотечением. Рус. мед. журн. 2006; 14 (15): 3–10. / Evseev M.A. NPVP-indutsirovannye gastroduodenal'nye iazvy, oslozhnennye krovotecheniem. Rus. med. zhurn. 2006; 14 (15): 3–10. [in Russian]
16. Singh et al. Gastrointestinal Tract Complications of Nonsteroidal Anti-inflammatory Drug Treatment in Rheumatoid Arthritis. Arch Intern Med 1996; 156: 1530–6.
17. Massó González EL et al. Variability among nonsteroidal antiinflammatory drugs in risk of upper gastrointestinal bleeding. Arthritis Rheum 2010; 62 (6): 1592–601.
18. Malfertheiner P et al. Management of Helicobacter pylori infection-the Maastricht V/Florence Consensus Report. Gut 2017; 66 (1): 6–30.
19. Lanza FL et al. Guidelines for prevention of NSAID-related ulcer complications. Am J Gastroenterol 2009; 104 (3): 728–38.
20. Rubenstein JH, Laine L. Systematic review: the hepatotoxicity of non-steroidal anti-inflammatory drugs. Aliment Pharmacol Ther 2004; 20 (4): 373–80.
21. Sanchez-Matienzo D. Hepatic disorders in patients treated with COX-2 selective inhibitors or nonselective NSAIDs: a case/noncase analysis of spontaneous reports. Clin Ther 2006; 28 (8): 1123–32.
22. García Rodríguez LA, Williams R, Derby LE et al. Acute liver injury associated with nonsteroidal anti-inflammatory drugs and the role of risk factors. Arch Intern Med 1994; 154 (3): 311–6.
23. Harris RC. Cyclooxygenase-2 and the kidney: functional and pathophysiological. J Hypertens 2002; 20: S3–S9.
24. Fagagnini S, Heinrich H et al. Risk factors for gallstones and kidney stones in a cohort of patients with inflammatory bowel diseases. PLoS One 2017; 12 (10): e0185193.
25. Ingrasciotta Y, Sultana J, Giorgianni F et al. Association of Individual Non-Steroidal Anti-Inflammatory Drugs and Chronic Kidney Disease: A Population-Based Case Control Study. PLoS ONE 2015; 10 (4): e0122899.
26. Ungprasert P, Cheungpasitporn W, Crowson CS. Matteson Individual non-steroidal anti-inflammatory drugs and risk of acute kidney injury: A systematic review and meta-analysis of observational studies. EL Eur J Intern Med 2015; 26 (4): 285.
2. Brune K, Patrignani P. New insights into the use of currently available non-steroidal anti-inflammatory drugs. J Pain Res 2015; 8: 105–18.
3. Smyth EM, Grosser T, Wang M et al. Prostanoids in health and disease. J Lipid Res 2009; 50: S423–8.
4. Grosser T, Fries S, FitzGerald GA. Biological basis for the cardiovascular consequences of COX-2 inhibition: therapeutic challenges and opportunities. J Clin Invest 2006; 116: 4–15.
5. Funk CD, FitzGerald GA. COX-2 inhibitors and cardiovascular risk. J Cardiovasc Pharmacol 2007; 50: 470-9.
6. Schmidt M, Lamberts M, Olsen AM et al. Cardiovascular safety of non-aspirin non-steroidal anti-inflammatory drugs: review and position paper by the working group of cardiovascular pharmacotherapy of the European Society of Cardiology. Eur Heart J 2016; 37: 1015–23.
7. Ye Y, Martinez JD, Perez-Polo RJ et al. The role of eNOS, iNOS, and NFkB in upregulation and activation of cyclooxygenase-2 and infarct size reduction by atorvastatin. Am J Physiol Heart Circ Physiol 2008; 295: 343–51.
8. Liuni A, Luca MC, Gori T, Parker JD. Rosuvastatin prevents conduit artery endothelial dysfunction induced by ischemia and reperfusion by a cyclooxygenase-2-dependent mechanism. J Am Coll Cardiol 2010; 55: 1002–6.
9. Johnson AG, Nguyen TV, Day RO. Do nonsteroidal anti-inflammatory drugs affect blood pressure? A meta-analysis. Ann Intern Med 1994; 121: 289–300.
10. Chan CC, Reid CM, Aw TJ. Do COX-2 inhibitors raise blood pressure more than nonselective NSAIDs and placebo? An updated meta-analysis et al. J Hypertens 2009; 27: 2332–41.
11. Trelle S, Reichenbach S et al. Cardiovascular safety of non-steroidal anti-inflammatory drugs: network meta-analysis. BMJ 2011; 342: с7086.
12. McGettigan P, Henry D. Cardiovascular Risk with Non-Steroidal Anti-Inflammatory Drugs: Systematic Review of Population-Based Controlled Observational Studies. PLoS Med 2011; 8 (9): e1001098.
13. https://www.fda.gov/Drugs/DrugSafety/ucm451800.htm
14. Nagata N, Niikura R et al. Lower GI bleeding risk of nonsteroidal anti-inflammatory drugs and antiplatelet drug use alone and the effect of combined therapy. Gastrointest Endosc 2014, Aug 1.
15. Евсеев М.А. НПВП-индуцированные гастродуоденальные язвы, осложненные кровотечением. Рус. мед. журн. 2006; 14 (15): 3–10. / Evseev M.A. NPVP-indutsirovannye gastroduodenal'nye iazvy, oslozhnennye krovotecheniem. Rus. med. zhurn. 2006; 14 (15): 3–10. [in Russian]
16. Singh et al. Gastrointestinal Tract Complications of Nonsteroidal Anti-inflammatory Drug Treatment in Rheumatoid Arthritis. Arch Intern Med 1996; 156: 1530–6.
17. Massó González EL et al. Variability among nonsteroidal antiinflammatory drugs in risk of upper gastrointestinal bleeding. Arthritis Rheum 2010; 62 (6): 1592–601.
18. Malfertheiner P et al. Management of Helicobacter pylori infection-the Maastricht V/Florence Consensus Report. Gut 2017; 66 (1): 6–30.
19. Lanza FL et al. Guidelines for prevention of NSAID-related ulcer complications. Am J Gastroenterol 2009; 104 (3): 728–38.
20. Rubenstein JH, Laine L. Systematic review: the hepatotoxicity of non-steroidal anti-inflammatory drugs. Aliment Pharmacol Ther 2004; 20 (4): 373–80.
21. Sanchez-Matienzo D. Hepatic disorders in patients treated with COX-2 selective inhibitors or nonselective NSAIDs: a case/noncase analysis of spontaneous reports. Clin Ther 2006; 28 (8): 1123–32.
22. García Rodríguez LA, Williams R, Derby LE et al. Acute liver injury associated with nonsteroidal anti-inflammatory drugs and the role of risk factors. Arch Intern Med 1994; 154 (3): 311–6.
23. Harris RC. Cyclooxygenase-2 and the kidney: functional and pathophysiological. J Hypertens 2002; 20: S3–S9.
24. Fagagnini S, Heinrich H et al. Risk factors for gallstones and kidney stones in a cohort of patients with inflammatory bowel diseases. PLoS One 2017; 12 (10): e0185193.
25. Ingrasciotta Y, Sultana J, Giorgianni F et al. Association of Individual Non-Steroidal Anti-Inflammatory Drugs and Chronic Kidney Disease: A Population-Based Case Control Study. PLoS ONE 2015; 10 (4): e0122899.
26. Ungprasert P, Cheungpasitporn W, Crowson CS. Matteson Individual non-steroidal anti-inflammatory drugs and risk of acute kidney injury: A systematic review and meta-analysis of observational studies. EL Eur J Intern Med 2015; 26 (4): 285.
2. Brune K, Patrignani P. New insights into the use of currently available non-steroidal anti-inflammatory drugs. J Pain Res 2015; 8: 105–18.
3. Smyth EM, Grosser T, Wang M et al. Prostanoids in health and disease. J Lipid Res 2009; 50: S423–8.
4. Grosser T, Fries S, FitzGerald GA. Biological basis for the cardiovascular consequences of COX-2 inhibition: therapeutic challenges and opportunities. J Clin Invest 2006; 116: 4–15.
5. Funk CD, FitzGerald GA. COX-2 inhibitors and cardiovascular risk. J Cardiovasc Pharmacol 2007; 50: 470-9.
6. Schmidt M, Lamberts M, Olsen AM et al. Cardiovascular safety of non-aspirin non-steroidal anti-inflammatory drugs: review and position paper by the working group of cardiovascular pharmacotherapy of the European Society of Cardiology. Eur Heart J 2016; 37: 1015–23.
7. Ye Y, Martinez JD, Perez-Polo RJ et al. The role of eNOS, iNOS, and NFkB in upregulation and activation of cyclooxygenase-2 and infarct size reduction by atorvastatin. Am J Physiol Heart Circ Physiol 2008; 295: 343–51.
8. Liuni A, Luca MC, Gori T, Parker JD. Rosuvastatin prevents conduit artery endothelial dysfunction induced by ischemia and reperfusion by a cyclooxygenase-2-dependent mechanism. J Am Coll Cardiol 2010; 55: 1002–6.
9. Johnson AG, Nguyen TV, Day RO. Do nonsteroidal anti-inflammatory drugs affect blood pressure? A meta-analysis. Ann Intern Med 1994; 121: 289–300.
10. Chan CC, Reid CM, Aw TJ. Do COX-2 inhibitors raise blood pressure more than nonselective NSAIDs and placebo? An updated meta-analysis et al. J Hypertens 2009; 27: 2332–41.
11. Trelle S, Reichenbach S et al. Cardiovascular safety of non-steroidal anti-inflammatory drugs: network meta-analysis. BMJ 2011; 342: с7086.
12. McGettigan P, Henry D. Cardiovascular Risk with Non-Steroidal Anti-Inflammatory Drugs: Systematic Review of Population-Based Controlled Observational Studies. PLoS Med 2011; 8 (9): e1001098.
13. https://www.fda.gov/Drugs/DrugSafety/ucm451800.htm
14. Nagata N, Niikura R et al. Lower GI bleeding risk of nonsteroidal anti-inflammatory drugs and antiplatelet drug use alone and the effect of combined therapy. Gastrointest Endosc 2014, Aug 1.
15. Евсеев М.А. НПВП-индуцированные гастродуоденальные язвы, осложненные кровотечением. Рус. мед. журн. 2006; 14 (15): 3–10. / Evseev M.A. NPVP-indutsirovannye gastroduodenal'nye iazvy, oslozhnennye krovotecheniem. Rus. med. zhurn. 2006; 14 (15): 3–10. [in Russian]
16. Singh et al. Gastrointestinal Tract Complications of Nonsteroidal Anti-inflammatory Drug Treatment in Rheumatoid Arthritis. Arch Intern Med 1996; 156: 1530–6.
17. Massó González EL et al. Variability among nonsteroidal antiinflammatory drugs in risk of upper gastrointestinal bleeding. Arthritis Rheum 2010; 62 (6): 1592–601.
18. Malfertheiner P et al. Management of Helicobacter pylori infection-the Maastricht V/Florence Consensus Report. Gut 2017; 66 (1): 6–30.
19. Lanza FL et al. Guidelines for prevention of NSAID-related ulcer complications. Am J Gastroenterol 2009; 104 (3): 728–38.
20. Rubenstein JH, Laine L. Systematic review: the hepatotoxicity of non-steroidal anti-inflammatory drugs. Aliment Pharmacol Ther 2004; 20 (4): 373–80.
21. Sanchez-Matienzo D. Hepatic disorders in patients treated with COX-2 selective inhibitors or nonselective NSAIDs: a case/noncase analysis of spontaneous reports. Clin Ther 2006; 28 (8): 1123–32.
22. García Rodríguez LA, Williams R, Derby LE et al. Acute liver injury associated with nonsteroidal anti-inflammatory drugs and the role of risk factors. Arch Intern Med 1994; 154 (3): 311–6.
23. Harris RC. Cyclooxygenase-2 and the kidney: functional and pathophysiological. J Hypertens 2002; 20: S3–S9.
24. Fagagnini S, Heinrich H et al. Risk factors for gallstones and kidney stones in a cohort of patients with inflammatory bowel diseases. PLoS One 2017; 12 (10): e0185193.
25. Ingrasciotta Y, Sultana J, Giorgianni F et al. Association of Individual Non-Steroidal Anti-Inflammatory Drugs and Chronic Kidney Disease: A Population-Based Case Control Study. PLoS ONE 2015; 10 (4): e0122899.
26. Ungprasert P, Cheungpasitporn W, Crowson CS. Matteson Individual non-steroidal anti-inflammatory drugs and risk of acute kidney injury: A systematic review and meta-analysis of observational studies. EL Eur J Intern Med 2015; 26 (4): 285.
________________________________________________
2. Brune K, Patrignani P. New insights into the use of currently available non-steroidal anti-inflammatory drugs. J Pain Res 2015; 8: 105–18.
3. Smyth EM, Grosser T, Wang M et al. Prostanoids in health and disease. J Lipid Res 2009; 50: S423–8.
4. Grosser T, Fries S, FitzGerald GA. Biological basis for the cardiovascular consequences of COX-2 inhibition: therapeutic challenges and opportunities. J Clin Invest 2006; 116: 4–15.
5. Funk CD, FitzGerald GA. COX-2 inhibitors and cardiovascular risk. J Cardiovasc Pharmacol 2007; 50: 470-9.
6. Schmidt M, Lamberts M, Olsen AM et al. Cardiovascular safety of non-aspirin non-steroidal anti-inflammatory drugs: review and position paper by the working group of cardiovascular pharmacotherapy of the European Society of Cardiology. Eur Heart J 2016; 37: 1015–23.
7. Ye Y, Martinez JD, Perez-Polo RJ et al. The role of eNOS, iNOS, and NFkB in upregulation and activation of cyclooxygenase-2 and infarct size reduction by atorvastatin. Am J Physiol Heart Circ Physiol 2008; 295: 343–51.
8. Liuni A, Luca MC, Gori T, Parker JD. Rosuvastatin prevents conduit artery endothelial dysfunction induced by ischemia and reperfusion by a cyclooxygenase-2-dependent mechanism. J Am Coll Cardiol 2010; 55: 1002–6.
9. Johnson AG, Nguyen TV, Day RO. Do nonsteroidal anti-inflammatory drugs affect blood pressure? A meta-analysis. Ann Intern Med 1994; 121: 289–300.
10. Chan CC, Reid CM, Aw TJ. Do COX-2 inhibitors raise blood pressure more than nonselective NSAIDs and placebo? An updated meta-analysis et al. J Hypertens 2009; 27: 2332–41.
11. Trelle S, Reichenbach S et al. Cardiovascular safety of non-steroidal anti-inflammatory drugs: network meta-analysis. BMJ 2011; 342: с7086.
12. McGettigan P, Henry D. Cardiovascular Risk with Non-Steroidal Anti-Inflammatory Drugs: Systematic Review of Population-Based Controlled Observational Studies. PLoS Med 2011; 8 (9): e1001098.
13. https://www.fda.gov/Drugs/DrugSafety/ucm451800.htm
14. Nagata N, Niikura R et al. Lower GI bleeding risk of nonsteroidal anti-inflammatory drugs and antiplatelet drug use alone and the effect of combined therapy. Gastrointest Endosc 2014, Aug 1.
15. Евсеев М.А. НПВП-индуцированные гастродуоденальные язвы, осложненные кровотечением. Рус. мед. журн. 2006; 14 (15): 3–10. / Evseev M.A. NPVP-indutsirovannye gastroduodenal'nye iazvy, oslozhnennye krovotecheniem. Rus. med. zhurn. 2006; 14 (15): 3–10. [in Russian]
16. Singh et al. Gastrointestinal Tract Complications of Nonsteroidal Anti-inflammatory Drug Treatment in Rheumatoid Arthritis. Arch Intern Med 1996; 156: 1530–6.
17. Massó González EL et al. Variability among nonsteroidal antiinflammatory drugs in risk of upper gastrointestinal bleeding. Arthritis Rheum 2010; 62 (6): 1592–601.
18. Malfertheiner P et al. Management of Helicobacter pylori infection-the Maastricht V/Florence Consensus Report. Gut 2017; 66 (1): 6–30.
19. Lanza FL et al. Guidelines for prevention of NSAID-related ulcer complications. Am J Gastroenterol 2009; 104 (3): 728–38.
20. Rubenstein JH, Laine L. Systematic review: the hepatotoxicity of non-steroidal anti-inflammatory drugs. Aliment Pharmacol Ther 2004; 20 (4): 373–80.
21. Sanchez-Matienzo D. Hepatic disorders in patients treated with COX-2 selective inhibitors or nonselective NSAIDs: a case/noncase analysis of spontaneous reports. Clin Ther 2006; 28 (8): 1123–32.
22. García Rodríguez LA, Williams R, Derby LE et al. Acute liver injury associated with nonsteroidal anti-inflammatory drugs and the role of risk factors. Arch Intern Med 1994; 154 (3): 311–6.
23. Harris RC. Cyclooxygenase-2 and the kidney: functional and pathophysiological. J Hypertens 2002; 20: S3–S9.
24. Fagagnini S, Heinrich H et al. Risk factors for gallstones and kidney stones in a cohort of patients with inflammatory bowel diseases. PLoS One 2017; 12 (10): e0185193.
25. Ingrasciotta Y, Sultana J, Giorgianni F et al. Association of Individual Non-Steroidal Anti-Inflammatory Drugs and Chronic Kidney Disease: A Population-Based Case Control Study. PLoS ONE 2015; 10 (4): e0122899.
26. Ungprasert P, Cheungpasitporn W, Crowson CS. Matteson Individual non-steroidal anti-inflammatory drugs and risk of acute kidney injury: A systematic review and meta-analysis of observational studies. EL Eur J Intern Med 2015; 26 (4): 285.
Авторы
Г.С.Аникин1*, И.В.Стожкова2, В.Г.Кукес1
1. ФГАОУ ВО «Первый Московский государственный медицинский университет им. И.М.Сеченова» Минздрава России. 119992, Россия, Москва, ул. Трубецкая, д. 8, стр. 2;
2. ФГБОУ ДПО «Российская медицинская академия непрерывного профессионального образования» Минздрава России. 125993, Россия, Москва, ул. Баррикадная, д. 2/1
*medi321@mail.ru
1. I.M.Sechenov First Moscow State Medical University of the Ministry of Health of the Russian Federation. 119992, Russian Federation, Moscow, ul. Trubetskaia, d. 8, str. 2;
2. Russian Medical Academy of Continuous Professional Education of the Ministry of Health of the Russian Federation. 125993, Russian Federation, Moscow, ul. Barrikadnaia, d. 2/1
*medi321@mail.ru
1. ФГАОУ ВО «Первый Московский государственный медицинский университет им. И.М.Сеченова» Минздрава России. 119992, Россия, Москва, ул. Трубецкая, д. 8, стр. 2;
2. ФГБОУ ДПО «Российская медицинская академия непрерывного профессионального образования» Минздрава России. 125993, Россия, Москва, ул. Баррикадная, д. 2/1
*medi321@mail.ru
________________________________________________
1. I.M.Sechenov First Moscow State Medical University of the Ministry of Health of the Russian Federation. 119992, Russian Federation, Moscow, ul. Trubetskaia, d. 8, str. 2;
2. Russian Medical Academy of Continuous Professional Education of the Ministry of Health of the Russian Federation. 125993, Russian Federation, Moscow, ul. Barrikadnaia, d. 2/1
*medi321@mail.ru
Цель портала OmniDoctor – предоставление профессиональной информации врачам, провизорам и фармацевтам.